Veloxis announces rescue rights offer
Danish bio-technology firm Veloxis Pharmaceuticals announced a disappointing set of results and a Dkr425m ($71m) rescue rights issue on Thursday. Handelsbanken is managing the deal but not underwriting as it will be fully supported by the firm’s two leading shareholders.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: